AORT

Artivion, Inc. (AORT) Q2 2026 Earnings Call Transcript

Second Quarter & Recent Business Highlights: Achieved revenue of $125.8 million in the second quarter of 2026 versus $113.0 million in the second quarter of 2025, an increase of 11% on a GAAP basis and 9% on a non-GAAP constant currency basis  Net loss for the second quarter of 2026 was $(13.5) million, or $(0.28) per fully diluted share, and non-GAAP net income was $6.3 million, or $0.13 per fully diluted share Adjusted EBITDA increased 7% to $26.4 million in the second quarter of 2026 compared to $24.8 million in the second quarter of 2025 Announced U.S. FDA PMA Approval of the AMDS Hybrid Prosthesis Completed acquisition of Endospan Ltd. ATLANTA, Aug. 6, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the second quarter ended June 30, 2026.

ATLANTA, July 28, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investor conferences. Artivion's management team will present at the upcoming Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026 at the InterContinental Boston Hotel.

ATLANTA, July 23, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that second quarter 2026 financial results will be released on Thursday, August 6, 2026, after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m.

AORT's FDA approval for AMDS removes a key hospital adoption hurdle and opens access to an estimated $150 million annual U.S. market.

Artivion benefits from FDA premarket approval of AMDS, removing adoption barriers and unlocking a $150M U.S. TAM in acute aortic dissection. AMDS's clinical data shows reduced mortality and major adverse events, with the elimination of DANE tears and durable benefit, supporting rapid, adoption-driven commercial scaling. AORT demonstrates double-digit revenue growth, margin expansion, and a shift to GAAP profitability, with EBITDA up 26% and gross margins nearing 65%.

ATLANTA, June 29, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug Administration (FDA) has approved the premarket approval application (PMA) for the AMDS Hybrid Prosthesis ("AMDS"). The approval covers acute Debakey Type I aortic dissections with either clinical or radiographic malperfusion, which the Company estimates to be approximately 60% of all Debakey Type I aortic dissections.

ATLANTA, June 10, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate at the upcoming 2026 Truist Securities MedTech Conference on Tuesday, June 16, 2026, at the Boston Harbor Hotel. The Company's fireside chat is scheduled to begin at 1:00 p.m.

ATLANTA, May 18, 2026 Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it has completed the acquisition of its long-standing partner Endospan Ltd. ("Endospan"), a pioneer in the endovascular repair of aortic arch disease  and developer of the NEXUS® Aortic Arch System.

MILWAUKEE, May 11, 2026 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Artivion (NYSE: AORT). The investigation results from inaccurate statements Artivion may have made regarding its financial statements, business operations and prospects.